Isolates 3995, 3988, OV209, 15009, and 5973 contained the suilysin gene, but did not express the protein under in vitro conditions (Table 1). Almost all isolates tested 5-Fluoracil in this study contained the mrp gene, whereas less than half expressed the protein under in vitro conditions (Table 1 and Figure 2) [13]. Figure 2 Presence/absence of 25 putative virulence genes represented in a dendrogram. Naming (SSU numbering) is derived

from the annotated genome sequence of P1/7 [7]. Presence of 25 described putative virulence factors was studied: muramidase released protein (mrp), and extracullar factor (epf) [13], suilysin (sly) [20], sortases (srtA, srtBCD, srtF) [34], surface antigen one (sao) [42], hyaluronidase (hylA) [17, 43], opacity factor (ofs) [37], fibronectin binding protein (fbps) [44], arginin deiminase (arcA) [45], glyceraldehyde-3-phosphate dehydrogenase (gapdh)

[46], regulator of virulence (revS) [35, 47], enolase (eno) [48], glutamine synthetase (glnA) [49], igA1 protease [36], inosine 5-monophosphate dehydrogenase (impdh) [50], dipeptidyl peptidase IV (dppIV) [51], ferrous iron transporter (feoB) [52], subtilisin like serine protease (sspA) [53], amylopullulanase (apuA) [54], ferric uptake regulator (fur), and adhesion competence repressor (adcR) [55]. * hylA is present as pseudogene in P1/7 and does not have a SSU-number. ‘+’ indicates all probes have a ratio > -1.5 (present); light grey shading indicates one or more probes have a ratio between -1.5 and -3 (present with slight variation); dark grey shading indicates one or more probes have a ratio between -3 and 4.5 {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| (present with large variation); ‘-’ indicates one or more probes have a ratio < -4.5 (partly or completely absent). Regions of differences and core genome of S. suis To further explore genetic diversity between S. suis isolates, regions of difference (RDs) were identified, which were defined as at least three consecutive ORFs that were absent from at least one strain. Thirty-nine RDs that varied in size from 461 bp to Sinomenine 27 kbp were identified. The largest RD (27 kbp) contained cps genes encoding serotype specific polysaccharide capsule of

P1/7 (serotype 2) (Table 3). Other RDs contained ABC transporters, restriction modification systems, signal peptidases (srtE, srtF), several transporters, two-component systems and several other genes (Table 3). Table 3 Regions of difference (RDs) identified in relation to P1/7. RD# Range in P1/7* Size (bp)* Present in n/55 strains (parts present in n/55) %GC$ Predicted Function* RD01 SSU0101 – SSU0111 7.537 23 (49) 34.1 Integrase, replication initiation factor, hypothetical proteins RD02 SSU0178 – SSU0182 5.501 47 40.8 PTS IIB, transketolase RD03 SSU0198 – SSU0209 14.234 37 (13) 33.7 PTS IIABC transporter, glucosamine-6-phosphate isomerase, pseudogene RD04 SSU0300 – SSU0305 5.455 36 (17) 43.0 Dehydrogenase, flavin oxidoreductase, transcription regulator lipase RD05 SSU0346 – SSU0350 7.680 29 38.